Loading…
Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting
Drug resistance displays a problem for the therapy of Mycobacterium tuberculosis infections. For molecular resistance testing, it is essential to have precise knowledge on genomic variations involved in resistance development. However, data from high-incidence settings are only sparely available. Th...
Saved in:
Published in: | BMC microbiology 2012-05, Vol.12 (1), p.90-90 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-b746t-8414831b4c2174f8c607b2be47aa9d4f42ca1b77a3fb08192156b548905a31593 |
---|---|
cites | cdi_FETCH-LOGICAL-b746t-8414831b4c2174f8c607b2be47aa9d4f42ca1b77a3fb08192156b548905a31593 |
container_end_page | 90 |
container_issue | 1 |
container_start_page | 90 |
container_title | BMC microbiology |
container_volume | 12 |
creator | Feuerriegel, Silke Oberhauser, Barbara George, Abu Garawani Dafae, Foday Richter, Elvira Rüsch-Gerdes, Sabine Niemann, Stefan |
description | Drug resistance displays a problem for the therapy of Mycobacterium tuberculosis infections. For molecular resistance testing, it is essential to have precise knowledge on genomic variations involved in resistance development. However, data from high-incidence settings are only sparely available. Therefore we performed a systematic approach and analyzed a total of 97 M. tuberculosis strains from previously treated patients in Sierra Leone for mutations in katG, rpoB, rrs, rpsL, gidB, embB, pncA and where applicable in inhA and ahpC. Of the strains investigated 50 were either mono- or poly-resistant to isoniazid, rifampin, streptomycin, ethambutol and pyrazinamide or MDR and 47 fully susceptible strains served as controls.
The majority of isoniazid and rifampin resistant strains had mutations in katG315 (71.9%) and rpoB531 (50%). However, rpoB mutations in codons 511, 516 and 533 were also detected in five rifampin susceptible strains. MIC determinations revealed low-level rifampin resistance for those strains. Thus, the sensitivity and specificity of sequencing of katG for detection of drug resistance were 86.7% and 100% and for sequencing of rpoB 100% and 93.8%, respectively.Strikingly, none of the streptomycin resistant strains had mutations in rrs, but 47.5% harboured mutations in rpsL. Further changes were detected in gidB. Among ethambutol resistant strains 46.7% had mutations at embB306. Pyrazinamide resistant strains displayed a variety of mutations throughout pncA. The specificities of sequencing of rpsL, embB and pncA for resistance detection were high (96-100%), whereas sensitivities were lower (48.8%, 73.3%, 70%).
Our study reveals a good correlation between data from molecular and phenotypic resistance testing in this high-incidence setting. However, the fact that particular mutations in rpoB are not linked to high-level resistance is challenging and demonstrates that careful interpretation of molecular resistance assays is mandatory. In addition, certain variations, especially in gidB, appear to be phylogenetically informative polymorphisms rather than markers for drug resistance. |
doi_str_mv | 10.1186/1471-2180-12-90 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bd7a5444104b4e68b7ecc55e3eaa7aa9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534123630</galeid><doaj_id>oai_doaj_org_article_bd7a5444104b4e68b7ecc55e3eaa7aa9</doaj_id><sourcerecordid>A534123630</sourcerecordid><originalsourceid>FETCH-LOGICAL-b746t-8414831b4c2174f8c607b2be47aa9d4f42ca1b77a3fb08192156b548905a31593</originalsourceid><addsrcrecordid>eNqFk0tv1DAQgCMEoqVw5oYicYFDWr8SOxektuKxUhEShbNlO5OsV4ldbAfRI_8cp1uWLipCPsQaf_PZmbGL4jlGxxiL5gQzjiuCBaowqVr0oDjcRR7emR8UT2LcIIS5oPxxcUBIwxqKxGHx8xK-zeAMlMqp8TraWPY-lB0kMMl6V_q-7G2IqRqtg7IL81AGyFhSS5J15cdr47UyCYKdpzLNGoKZR7-YYgrKumwMfipVubbDurLO2O5mwwgpWTc8LR71aozw7PZ7VHx99_bL-Yfq4tP71fnpRaU5a1IlGGaCYs0MwZz1wjSIa6KBcaXajvWMGIU154r2GgncElw3umaiRbWiuG7pUbHaejuvNvIq2EmFa-mVlTcBHwapQrJmBKk7rmrGGEZMM2iE5mBMXQMFpZbtsuvN1nU16wk6Ay7_6bgn3V9xdi0H_11ShljLaBacbQXa-n8I9leMn-TSTrm0U2IiW5Qlr25PEXxuYkxystHAOCoHfo4SUyJqjDCt_48iihCvCccZffkXuvFzyJdjoUgrGsxJ84caVC6Ydb3PxzSLVJ7WlGFC8_3K1PE9VB4dTNZ4B73N8b2E13sJmUnwIw1qjlGuLj_vsydb1gQfY4B-Vz6cK5Rfxz0Fe3G3bTv-93OgvwCBUwmN</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1029861726</pqid></control><display><type>article</type><title>Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting</title><source>PubMed Central Free</source><source>Publicly Available Content Database</source><creator>Feuerriegel, Silke ; Oberhauser, Barbara ; George, Abu Garawani ; Dafae, Foday ; Richter, Elvira ; Rüsch-Gerdes, Sabine ; Niemann, Stefan</creator><creatorcontrib>Feuerriegel, Silke ; Oberhauser, Barbara ; George, Abu Garawani ; Dafae, Foday ; Richter, Elvira ; Rüsch-Gerdes, Sabine ; Niemann, Stefan</creatorcontrib><description>Drug resistance displays a problem for the therapy of Mycobacterium tuberculosis infections. For molecular resistance testing, it is essential to have precise knowledge on genomic variations involved in resistance development. However, data from high-incidence settings are only sparely available. Therefore we performed a systematic approach and analyzed a total of 97 M. tuberculosis strains from previously treated patients in Sierra Leone for mutations in katG, rpoB, rrs, rpsL, gidB, embB, pncA and where applicable in inhA and ahpC. Of the strains investigated 50 were either mono- or poly-resistant to isoniazid, rifampin, streptomycin, ethambutol and pyrazinamide or MDR and 47 fully susceptible strains served as controls.
The majority of isoniazid and rifampin resistant strains had mutations in katG315 (71.9%) and rpoB531 (50%). However, rpoB mutations in codons 511, 516 and 533 were also detected in five rifampin susceptible strains. MIC determinations revealed low-level rifampin resistance for those strains. Thus, the sensitivity and specificity of sequencing of katG for detection of drug resistance were 86.7% and 100% and for sequencing of rpoB 100% and 93.8%, respectively.Strikingly, none of the streptomycin resistant strains had mutations in rrs, but 47.5% harboured mutations in rpsL. Further changes were detected in gidB. Among ethambutol resistant strains 46.7% had mutations at embB306. Pyrazinamide resistant strains displayed a variety of mutations throughout pncA. The specificities of sequencing of rpsL, embB and pncA for resistance detection were high (96-100%), whereas sensitivities were lower (48.8%, 73.3%, 70%).
Our study reveals a good correlation between data from molecular and phenotypic resistance testing in this high-incidence setting. However, the fact that particular mutations in rpoB are not linked to high-level resistance is challenging and demonstrates that careful interpretation of molecular resistance assays is mandatory. In addition, certain variations, especially in gidB, appear to be phylogenetically informative polymorphisms rather than markers for drug resistance.</description><identifier>ISSN: 1471-2180</identifier><identifier>EISSN: 1471-2180</identifier><identifier>DOI: 10.1186/1471-2180-12-90</identifier><identifier>PMID: 22646308</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antibiotics ; Antitubercular agents ; Antitubercular Agents - pharmacology ; Bacterial Proteins - genetics ; Codon ; DNA, Bacterial - chemistry ; DNA, Bacterial - genetics ; Drug resistance ; Drug resistance in microorganisms ; Drug Resistance, Bacterial ; Drug therapy ; Genetic aspects ; Genetic variation ; Genotype ; Health aspects ; Humans ; Incidence ; Microbial Sensitivity Tests - methods ; Mortality ; Mutation ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - genetics ; Mycobacterium tuberculosis - isolation & purification ; Sensitivity and Specificity ; Sequence Analysis, DNA - methods ; Sierra Leone - epidemiology ; Tuberculosis ; Tuberculosis - epidemiology ; Tuberculosis - microbiology</subject><ispartof>BMC microbiology, 2012-05, Vol.12 (1), p.90-90</ispartof><rights>COPYRIGHT 2012 BioMed Central Ltd.</rights><rights>2012 Feuerriegel et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright ©2012 Feuerriegel et al.; licensee BioMed Central Ltd. 2012 Feuerriegel et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b746t-8414831b4c2174f8c607b2be47aa9d4f42ca1b77a3fb08192156b548905a31593</citedby><cites>FETCH-LOGICAL-b746t-8414831b4c2174f8c607b2be47aa9d4f42ca1b77a3fb08192156b548905a31593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404943/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1029861726?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22646308$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feuerriegel, Silke</creatorcontrib><creatorcontrib>Oberhauser, Barbara</creatorcontrib><creatorcontrib>George, Abu Garawani</creatorcontrib><creatorcontrib>Dafae, Foday</creatorcontrib><creatorcontrib>Richter, Elvira</creatorcontrib><creatorcontrib>Rüsch-Gerdes, Sabine</creatorcontrib><creatorcontrib>Niemann, Stefan</creatorcontrib><title>Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting</title><title>BMC microbiology</title><addtitle>BMC Microbiol</addtitle><description>Drug resistance displays a problem for the therapy of Mycobacterium tuberculosis infections. For molecular resistance testing, it is essential to have precise knowledge on genomic variations involved in resistance development. However, data from high-incidence settings are only sparely available. Therefore we performed a systematic approach and analyzed a total of 97 M. tuberculosis strains from previously treated patients in Sierra Leone for mutations in katG, rpoB, rrs, rpsL, gidB, embB, pncA and where applicable in inhA and ahpC. Of the strains investigated 50 were either mono- or poly-resistant to isoniazid, rifampin, streptomycin, ethambutol and pyrazinamide or MDR and 47 fully susceptible strains served as controls.
The majority of isoniazid and rifampin resistant strains had mutations in katG315 (71.9%) and rpoB531 (50%). However, rpoB mutations in codons 511, 516 and 533 were also detected in five rifampin susceptible strains. MIC determinations revealed low-level rifampin resistance for those strains. Thus, the sensitivity and specificity of sequencing of katG for detection of drug resistance were 86.7% and 100% and for sequencing of rpoB 100% and 93.8%, respectively.Strikingly, none of the streptomycin resistant strains had mutations in rrs, but 47.5% harboured mutations in rpsL. Further changes were detected in gidB. Among ethambutol resistant strains 46.7% had mutations at embB306. Pyrazinamide resistant strains displayed a variety of mutations throughout pncA. The specificities of sequencing of rpsL, embB and pncA for resistance detection were high (96-100%), whereas sensitivities were lower (48.8%, 73.3%, 70%).
Our study reveals a good correlation between data from molecular and phenotypic resistance testing in this high-incidence setting. However, the fact that particular mutations in rpoB are not linked to high-level resistance is challenging and demonstrates that careful interpretation of molecular resistance assays is mandatory. In addition, certain variations, especially in gidB, appear to be phylogenetically informative polymorphisms rather than markers for drug resistance.</description><subject>Analysis</subject><subject>Antibiotics</subject><subject>Antitubercular agents</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Bacterial Proteins - genetics</subject><subject>Codon</subject><subject>DNA, Bacterial - chemistry</subject><subject>DNA, Bacterial - genetics</subject><subject>Drug resistance</subject><subject>Drug resistance in microorganisms</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug therapy</subject><subject>Genetic aspects</subject><subject>Genetic variation</subject><subject>Genotype</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Incidence</subject><subject>Microbial Sensitivity Tests - methods</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - genetics</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Sensitivity and Specificity</subject><subject>Sequence Analysis, DNA - methods</subject><subject>Sierra Leone - epidemiology</subject><subject>Tuberculosis</subject><subject>Tuberculosis - epidemiology</subject><subject>Tuberculosis - microbiology</subject><issn>1471-2180</issn><issn>1471-2180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFk0tv1DAQgCMEoqVw5oYicYFDWr8SOxektuKxUhEShbNlO5OsV4ldbAfRI_8cp1uWLipCPsQaf_PZmbGL4jlGxxiL5gQzjiuCBaowqVr0oDjcRR7emR8UT2LcIIS5oPxxcUBIwxqKxGHx8xK-zeAMlMqp8TraWPY-lB0kMMl6V_q-7G2IqRqtg7IL81AGyFhSS5J15cdr47UyCYKdpzLNGoKZR7-YYgrKumwMfipVubbDurLO2O5mwwgpWTc8LR71aozw7PZ7VHx99_bL-Yfq4tP71fnpRaU5a1IlGGaCYs0MwZz1wjSIa6KBcaXajvWMGIU154r2GgncElw3umaiRbWiuG7pUbHaejuvNvIq2EmFa-mVlTcBHwapQrJmBKk7rmrGGEZMM2iE5mBMXQMFpZbtsuvN1nU16wk6Ay7_6bgn3V9xdi0H_11ShljLaBacbQXa-n8I9leMn-TSTrm0U2IiW5Qlr25PEXxuYkxystHAOCoHfo4SUyJqjDCt_48iihCvCccZffkXuvFzyJdjoUgrGsxJ84caVC6Ydb3PxzSLVJ7WlGFC8_3K1PE9VB4dTNZ4B73N8b2E13sJmUnwIw1qjlGuLj_vsydb1gQfY4B-Vz6cK5Rfxz0Fe3G3bTv-93OgvwCBUwmN</recordid><startdate>20120530</startdate><enddate>20120530</enddate><creator>Feuerriegel, Silke</creator><creator>Oberhauser, Barbara</creator><creator>George, Abu Garawani</creator><creator>Dafae, Foday</creator><creator>Richter, Elvira</creator><creator>Rüsch-Gerdes, Sabine</creator><creator>Niemann, Stefan</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120530</creationdate><title>Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting</title><author>Feuerriegel, Silke ; Oberhauser, Barbara ; George, Abu Garawani ; Dafae, Foday ; Richter, Elvira ; Rüsch-Gerdes, Sabine ; Niemann, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b746t-8414831b4c2174f8c607b2be47aa9d4f42ca1b77a3fb08192156b548905a31593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Analysis</topic><topic>Antibiotics</topic><topic>Antitubercular agents</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Bacterial Proteins - genetics</topic><topic>Codon</topic><topic>DNA, Bacterial - chemistry</topic><topic>DNA, Bacterial - genetics</topic><topic>Drug resistance</topic><topic>Drug resistance in microorganisms</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug therapy</topic><topic>Genetic aspects</topic><topic>Genetic variation</topic><topic>Genotype</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Incidence</topic><topic>Microbial Sensitivity Tests - methods</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - genetics</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Sensitivity and Specificity</topic><topic>Sequence Analysis, DNA - methods</topic><topic>Sierra Leone - epidemiology</topic><topic>Tuberculosis</topic><topic>Tuberculosis - epidemiology</topic><topic>Tuberculosis - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feuerriegel, Silke</creatorcontrib><creatorcontrib>Oberhauser, Barbara</creatorcontrib><creatorcontrib>George, Abu Garawani</creatorcontrib><creatorcontrib>Dafae, Foday</creatorcontrib><creatorcontrib>Richter, Elvira</creatorcontrib><creatorcontrib>Rüsch-Gerdes, Sabine</creatorcontrib><creatorcontrib>Niemann, Stefan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feuerriegel, Silke</au><au>Oberhauser, Barbara</au><au>George, Abu Garawani</au><au>Dafae, Foday</au><au>Richter, Elvira</au><au>Rüsch-Gerdes, Sabine</au><au>Niemann, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting</atitle><jtitle>BMC microbiology</jtitle><addtitle>BMC Microbiol</addtitle><date>2012-05-30</date><risdate>2012</risdate><volume>12</volume><issue>1</issue><spage>90</spage><epage>90</epage><pages>90-90</pages><issn>1471-2180</issn><eissn>1471-2180</eissn><abstract>Drug resistance displays a problem for the therapy of Mycobacterium tuberculosis infections. For molecular resistance testing, it is essential to have precise knowledge on genomic variations involved in resistance development. However, data from high-incidence settings are only sparely available. Therefore we performed a systematic approach and analyzed a total of 97 M. tuberculosis strains from previously treated patients in Sierra Leone for mutations in katG, rpoB, rrs, rpsL, gidB, embB, pncA and where applicable in inhA and ahpC. Of the strains investigated 50 were either mono- or poly-resistant to isoniazid, rifampin, streptomycin, ethambutol and pyrazinamide or MDR and 47 fully susceptible strains served as controls.
The majority of isoniazid and rifampin resistant strains had mutations in katG315 (71.9%) and rpoB531 (50%). However, rpoB mutations in codons 511, 516 and 533 were also detected in five rifampin susceptible strains. MIC determinations revealed low-level rifampin resistance for those strains. Thus, the sensitivity and specificity of sequencing of katG for detection of drug resistance were 86.7% and 100% and for sequencing of rpoB 100% and 93.8%, respectively.Strikingly, none of the streptomycin resistant strains had mutations in rrs, but 47.5% harboured mutations in rpsL. Further changes were detected in gidB. Among ethambutol resistant strains 46.7% had mutations at embB306. Pyrazinamide resistant strains displayed a variety of mutations throughout pncA. The specificities of sequencing of rpsL, embB and pncA for resistance detection were high (96-100%), whereas sensitivities were lower (48.8%, 73.3%, 70%).
Our study reveals a good correlation between data from molecular and phenotypic resistance testing in this high-incidence setting. However, the fact that particular mutations in rpoB are not linked to high-level resistance is challenging and demonstrates that careful interpretation of molecular resistance assays is mandatory. In addition, certain variations, especially in gidB, appear to be phylogenetically informative polymorphisms rather than markers for drug resistance.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>22646308</pmid><doi>10.1186/1471-2180-12-90</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2180 |
ispartof | BMC microbiology, 2012-05, Vol.12 (1), p.90-90 |
issn | 1471-2180 1471-2180 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_bd7a5444104b4e68b7ecc55e3eaa7aa9 |
source | PubMed Central Free; Publicly Available Content Database |
subjects | Analysis Antibiotics Antitubercular agents Antitubercular Agents - pharmacology Bacterial Proteins - genetics Codon DNA, Bacterial - chemistry DNA, Bacterial - genetics Drug resistance Drug resistance in microorganisms Drug Resistance, Bacterial Drug therapy Genetic aspects Genetic variation Genotype Health aspects Humans Incidence Microbial Sensitivity Tests - methods Mortality Mutation Mycobacterium tuberculosis Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - genetics Mycobacterium tuberculosis - isolation & purification Sensitivity and Specificity Sequence Analysis, DNA - methods Sierra Leone - epidemiology Tuberculosis Tuberculosis - epidemiology Tuberculosis - microbiology |
title | Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T00%3A56%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequence%20analysis%20for%20detection%20of%20first-line%20drug%20resistance%20in%20Mycobacterium%20tuberculosis%20strains%20from%20a%20high-incidence%20setting&rft.jtitle=BMC%20microbiology&rft.au=Feuerriegel,%20Silke&rft.date=2012-05-30&rft.volume=12&rft.issue=1&rft.spage=90&rft.epage=90&rft.pages=90-90&rft.issn=1471-2180&rft.eissn=1471-2180&rft_id=info:doi/10.1186/1471-2180-12-90&rft_dat=%3Cgale_doaj_%3EA534123630%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b746t-8414831b4c2174f8c607b2be47aa9d4f42ca1b77a3fb08192156b548905a31593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1029861726&rft_id=info:pmid/22646308&rft_galeid=A534123630&rfr_iscdi=true |